ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults

Not Applicable

Completed

Conditions: Nasolabial Fold

Interventions: Device: Restylane®
Device: JUVÉDERM® VOLIFT® with Lidocaine

First Posted Date: 2015-09-23

Last Posted Date: 2017-08-30

Lead Sponsor: Allergan

Target Recruit Count: 175

Registration Number: NCT02558283

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
General Hospital of Guangzhou Military Command of PLA, Guangzhou, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Guangzhou, China

and more 2 locations

Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: Alcaftadine Ophthalmic Solution 0.25%

First Posted Date: 2015-09-22

Last Posted Date: 2019-07-05

Lead Sponsor: Allergan

Target Recruit Count: 3423

Registration Number: NCT02555761

Locations: 🇰🇷
Ian Eye Center, Seoul, Korea, Republic of
🇰🇷
Soonchunhyang University Cheonan Hospital, Chungcheongnam-do, Korea, Republic of
🇰🇷
St. Mary's Eye center, Geyonggi-do, Korea, Republic of

and more 73 locations

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Cyclosporine 0.05% Ophthalmic Emulsion

First Posted Date: 2015-09-21

Last Posted Date: 2017-06-01

Lead Sponsor: Allergan

Target Recruit Count: 51

Registration Number: NCT02554981

Locations: 🇺🇸
Andover Eye Associates, Inc, Andover, Massachusetts, United States
🇺🇸
Total Eye Care, PA, Memphis, Tennessee, United States

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Sodium 0.5%
Drug: Carboxymethylcellulose Based Eye Drop

First Posted Date: 2015-09-18

Last Posted Date: 2017-11-17

Lead Sponsor: Allergan

Target Recruit Count: 242

Registration Number: NCT02553772

Locations: 🇺🇸
Havana Research Institute LLC, Burbank, California, United States
🇦🇺
The University of New South Wales School of Optometry and Vision Science, Sydney, Australia
🇺🇸
Lugene Eye Institute, Glendale, California, United States

and more 10 locations

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: Bimatoprost cutaneous solution 0.03%

First Posted Date: 2015-07-22

Last Posted Date: 2018-08-14

Lead Sponsor: Allergan

Target Recruit Count: 1699

Registration Number: NCT02505776

Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®

Completed

Conditions: Migraine Disorders

Interventions: Other: No Intervention

First Posted Date: 2015-07-20

Last Posted Date: 2019-04-05

Lead Sponsor: Allergan

Target Recruit Count: 215

Registration Number: NCT02502123

Locations: 🇨🇦
Toronto Headache & Pain Centre, North York, Ontario, Canada
🇨🇦
Hany Demian, Oakville, Ontario, Canada
🇨🇦
The Shapero Markham Headache and Pain Treatment Centre, Markham, Ontario, Canada

and more 12 locations

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

Phase 2

Completed

Conditions: Hyperhidrosis

Interventions: Biological: Vehicle
Biological: ANT-1207

First Posted Date: 2015-06-24

Last Posted Date: 2017-09-20

Lead Sponsor: Allergan

Target Recruit Count: 145

Registration Number: NCT02479139

Locations: 🇺🇸
Baumann Cosmetic & Research Institute, Miami, Florida, United States
🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States
🇺🇸
Shideler Clinical Research Center, Carmel, Indiana, United States

and more 16 locations

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar Pegol
Drug: Ranibizumab
Other: Sham Procedure

First Posted Date: 2015-06-04

Last Posted Date: 2020-07-30

Lead Sponsor: Allergan

Target Recruit Count: 949

Registration Number: NCT02462486

Locations: 🇺🇸
Paducah Retinal Center, Paducah, Kentucky, United States
🇺🇸
Maculacare - New York, New York, New York, United States
🇺🇸
Retina Vitreous Surgeons of Central NY, PC, Syracuse, New York, United States

and more 184 locations

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar Pegol
Drug: Ranibizumab
Other: Sham Procedure

First Posted Date: 2015-06-04

Last Posted Date: 2020-07-28

Lead Sponsor: Allergan

Target Recruit Count: 939

Registration Number: NCT02462928

Locations: 🇨🇱
Instituto Oftalmologica Profesor Arentsen, Santiago, Región Metropolitana, Chile
🇵🇭
Asian Eye Institute, Makati City, Metro Manila, Philippines
🇵🇭
St. Luke's Medical Center, Quezon City, Metro Manila, Philippines

and more 148 locations

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Sodium Based Eye Drops
Drug: Systane® Gel Drops
Drug: Genteal® Lubricant Gel Drops

First Posted Date: 2015-05-27

Last Posted Date: 2017-01-04

Lead Sponsor: Allergan

Target Recruit Count: 79

Registration Number: NCT02455050

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy